GB1535215A — Kanamycin derivatives
Assigned to Bristol Myers Co · Expires 1978-12-13 · 47y expired
What this patent protects
Semisynthetic derivatives of kanamycin A and B of the formula IV in which R3 and R have the meaning stated in Claim 1 are prepared. The process starts from corresponding compounds with R = hydrogen and comprises acylation with an acylating agent of the formula VII in which W and …
USPTO Abstract
Semisynthetic derivatives of kanamycin A and B of the formula IV in which R3 and R have the meaning stated in Claim 1 are prepared. The process starts from corresponding compounds with R = hydrogen and comprises acylation with an acylating agent of the formula VII in which W and M have the meaning stated in Claim 1, and subsequent elimination of the amino protective group W. A preferred acylating agent of the formula VIIa is obtained in situ by mixing the appropriate N-protected carboxylic acid with equimolar amounts of N-hydroxy-5-norbornene-2,3-dicarboximide and dicyclohexylcarbodiimide as dehydrating agent. The said compounds have antibacterial activity and can therefore be used in medicines or as additives to animal feedstuffs. <IMAGE>
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.